Bevacizumab prevents brain metastases formation in lung adenocarcinoma

Molecular Cancer Therapeutics

Volumn 15, Issue 4, 2016, Pages 702-710

  Ilhan Mutlu, Aysegül ^a,b,c   Osswald, Matthias ^a,d   Liao, Yunxiang ^a   Gömmel, Miriam ^a   Reck, Martin ^e   Miles, David ^f   Mariani, Paola ^g   Gianni, Luca ^h   Lutiger, Beatrix ⁱ   Nendel, Viktor ^j   Srock, Stefanie ⁱ   Perez Moreno, Pablo ⁱ   Thorsen, Frits ^k   Von Baumgarten, Louisa ^l   Preusser, Matthias ^b,c   Wick, Wolfgang ^a,d   Winkler, Frank ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Central Nervous System Tumors Unit   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Member of the German Center for Lung Research   (Germany)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j DASTA GmbH   (Germany)

^k UNIVERSITY OF BERGEN   (Norway)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; IMMUNOGLOBULIN G; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; INTRAVITAL MICROSCOPY; LUNG ADENOCARCINOMA; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADENOCARCINOMA; ANIMAL; BRAIN NEOPLASMS; CANCER STAGING; DISEASE MODEL; DRUG SCREENING; HUMAN; INCIDENCE; LUNG TUMOR; MORTALITY; MULTICENTER STUDY (TOPIC); NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY; TUMOR CELL LINE; TUMOR RECURRENCE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; INCIDENCE; LUNG NEOPLASMS; MICE; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964344560     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0582     Document Type: Article

References (36)

1. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012;32:4655-62.
2. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol 2012;14:1171-7.
3. Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 2007;109:1668-75.
4. Ding X, Dai H, Hui Z, Ji W, Liang J, Lv J, et al. Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer. Radiat Oncol 2012;7:119.
5. Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-7.
6. De Santis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
7. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 2013;31:65-72.
8. Ahluwalia MS, Winkler F. Targeted and immunotherapeutic approaches in brain metastases. Am Soc Clin Oncol Educ Book 2015;35:67-74.
9. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
10. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-22.
11. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology ofmetastasis to a sanctuary site. Clin Cancer Res 2007;13:1656-62.
12. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53-7.
13. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.
14. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-61.
15. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:20-30.
16. Lauro S, Onesti CE, Righini R, Marchetti P. The use of bevacizumab in nonsmall cell lung cancer: an update. Anticancer Res 2014;34:1537-45.
17. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
18. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013;31:1719-25.
19. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
20. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
21. Yano S, Nokihara H, Hanibuchi M, Parajuli P, Shinohara T, Kawano T, et al. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol Res 1997;9:573-9.
22. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60:4959-67.
23. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011;17:6192-205.
24. Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 2005;41:555-63.
25. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
26. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
27. Fu Y, Hu J, Du N, Jiao S, Li F, Li X, et al. Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. J Chemother. 2015 Jun. 3. [Epub ahead of print].
28. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.
29. Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 2013;73:2743-8.
30. Ito T, Kitamura H, Nakamura N, Kameda Y, Kanisawa M. A comparative study of vascular proliferation in brain metastasis of lung carcinomas. Virchows Arch A Pathol Anat Histopathol 1993;423:13-7.
31. Yuan A, Yang PC, Yu CJ, Lee YC, Yao YT, Chen CL, et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 1995;152:2157-62.
32. Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 andmetronomic chemotherapy limits metastatic growth. Cancer Cell 2014;26:880-95.
33. Steeg PS. Perspective: the right trials. Nature 2012;485:S58-9.
34. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31:3800-6.
35. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-84.
36. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients withlocally advancednon-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011;29:272-8.